[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCXKx6UH0aqXr4H4IByViXL0zo4kNEgZsKbwlDQjQmSQ":3},{"answer":4,"createTime":5,"id":6,"options":7,"origin":12,"question":18,"related":19,"source":27,"type":42},[],"2026-04-07 21:12:46",1087503662,[8,9,10,11],"腋窝淋巴结≥4个阳性","腋窝淋巴结1~3个阳性但同时伴有组织学分级为III级、T ≥5cm、 Ki67 ≥20%等危险因素之一者","初始治疗推荐AI治疗5年联合阿贝西利治疗2年","初始治疗可选择AI治疗5年",{"courseId":13,"courseImg":14,"courseName":15,"workId":16,"workName":17},"1000068648","https:\u002F\u002Ftihai-oss-cloud.itihey.com\u002Fimg\u002Ffd8cd4ffaa0c7b282a280f65c2ed3f0e.jpg","肿瘤学","63878634","第三章单元测试","对于绝经后的高复发风险乳腺癌患者,以下哪些描述是正确的( )",[20,29,34,39,43],{"answer":21,"createTime":5,"id":22,"options":23,"question":26,"source":27,"type":28},[],1087503646,[24,25],"对","错","对HR+、HER2-乳腺癌,腋窝淋巴结转移≥4个或腋窝淋巴结转移1-3个但同时伴有其他高危因素的患者属于高复发风险的患者,推荐选用AC-T治疗方案.( )","v2",3,{"answer":30,"createTime":5,"id":31,"options":32,"question":33,"source":27,"type":28},[],1087503649,[24,25],"对接受新辅助化疗后临床完全缓解的乳腺癌患者,可不接受后续的手术及术后辅助治疗.( )",{"answer":35,"createTime":5,"id":36,"options":37,"question":38,"source":27,"type":28},[],1087503655,[24,25],"对于乳腺癌根治性切除后患者,T3-4、腋窝淋巴结阳性的患者需要行放疗,而前哨淋巴结阳性及未行腋窝清扫的患者不需行放疗.( )",{"answer":40,"createTime":5,"id":6,"options":41,"question":18,"source":27,"type":42},[],[8,9,10,11],1,{"answer":44,"createTime":5,"id":45,"options":46,"question":51,"source":27,"type":52},[],1087503665,[47,48,49,50],"来曲唑","阿那曲唑","他莫昔芬","依西美坦","对乳腺癌内分泌治疗药物,以下不属于芳香化酶抑制剂的是( )",0]